Objectives:We aimed to compare the clinical results and topographic data of the new generation hybrid contact lens (HCL) and rigid gaspermeable contact lens (RGPCL) in patients with moderate and advanced keratoconus.
Materials and Methods:In this prospective study, HCL users comprised group 1 and RGPCL users comprised group 2. Snellen uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), and lens-corrected visual acuity (LCVA); manifest spherical-cylindrical values; corneal topography measurements (flat keratometry [K1], vertical keratometry [K2], mean K, maximum K [K max ], central corneal thickness [CCT], and thinnest corneal thickness [TCT]); and cone location were recorded.
Results:The study included 83 eyes of 51 patients in group 1 and 61 eyes of 40 patients in group 2. The groups were similar in age and gender (p>0.05). Mean LCVA (logMAR) was significantly lower than BCVA in both groups (p<0.001). The mean visual gain with contact lenses (Snellen chart) was 3.4±1.8 lines in group 1 and 4.0±2.1 lines in group 2. There was no significant difference between the two groups in BCVA, LCVA, or lines gained (p>0.05). There was also no significant difference between the two groups in terms of keratoconus stages, mean K max , CCT, TCT, or cone location (p>0.05), while mean UCVA (logMAR) and mean K were higher in group 2 (p<0.05). In both groups, the visual gain with lenses was higher in eyes with central cones, and there was significantly greater visual increase in group 2 (p=0.039).
Conclusion:In moderate and advanced keratoconus, HCLs improved vision as much as RGPCLs and both lenses were more effective for central
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.